Cadence Bancorpation has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price its 7.5 million shares in the range of $19 to $21 per share, with an overallotment option for an additional 1.125 million shares. At the maximum price, the entire offering is valued up to $181.125 million. The company has been authorized to list its shares on the New York Stock Exchange under the symbol CADE.
The underwriters for the offering are Goldman Sachs, JPMorgan, Sandler O’Neill, Keefe Bruyette & Woods, Baird, Raymond James, Stephens, SunTrust Robinson Humphrey and Tudor Pickering Holt.
This is a bank holding company and a Delaware corporation headquartered in Houston, Texas, and is the parent company of Cadence Bank, N.A. Formed in 2009 by banking industry veterans, Cadence secured $1.0 billion of capital commitments in 2010 and built its franchise on the heels of three successful acquisitions: Cadence Bank, N.A., in March 2011; the franchise of Superior Bank in April 2011; and Encore Bank, N.A., in July 2012.
Currently Cadence is a growth-oriented, middle-market focused commercial relationship bank providing a broad range of banking and wealth management services to businesses, high net worth individuals, business owners and retail customers through a network of 66 branches, as of December 31, 2016, with branches in Alabama (25), Florida (14), Texas (12), Mississippi (11) and Tennessee (four).
At the end of 2016, the company had $9.5 billion of assets, $7.4 billion of gross loans, $8.0 billion in deposits and $1.1 billion in shareholder’s equity. It generated $65.8 million and $39.3 million of net income for the years ended December 31, 2016, and 2015, respectively.
Cadence intends to use the net proceeds from this offering to support its organic growth and for general corporate purposes, which may include repayment of debt, maintenance of required regulatory capital and potential future acquisition opportunities, although the firm made no specific indications.